Table 3.

Comparison of Class I, Level A Recommendations: Harvoni and Viekira Pak¹⁸–²⁰,²⁶–²⁸

	Harvoni (LDV/SOF)			Viekira Pak (OBV/PTV/r + DSV ± RBV)
Trial Name	ION I	ION II	ION III	SAPPHIRE I	PEARL III	PEARL IV	TURQUOISE II
Study population	Treatment-naïve	GT 1 null-responders	Treatment-naïve with no cirrhosis	Treatment-naïve with no cirrhosis	GT 1b treatment-naïve with no cirrhosis	GT 1a treatment-naïve with no cirrhosis	Compensated cirrhosis
Treatment regimen	LDV/SOF ± RBV	LDV/SOF ± RBV	LDV/SOF ± RBV	OBV/PTV/r + DSV + RBV	OBV/PTV/r + DSV ± RBV	OBV/PTV/r + DSV ± RBV	OBV/PTV/r + DSV + RBV
Number of patients enrolled	865	440	647	631	419	305	380
Treatment duration	12 or 24 weeks	12 or 24 weeks	8 or 12 weeks	12 weeks	12 weeks	12 weeks	12 or 24 weeks
SVR12	97%–99%	94%–99%	93%–95%	96.2%	99.5%–99.0%	90.2%–97%	91.8%–95.9%
Relapse	2	11	23	7	1	11	13
Breakthrough	0	1	0	1	0	7	4
Discontinuation due to adverse events	0	0	3	4	0	2	8

DSV = dasabuvir; GT = genotype; LDV = ledipasvir; OBV = ombitasvir; PTV = paritaprevir; r = ritonavir; RBV = ribavirin; SOF = sofosbuvir; SVR12 = sustained virological response 12 weeks after treatment